

**A NOTE ON THE GLOBAL PROPERTIES OF AN
AGE-STRUCTURED VIRAL DYNAMIC MODEL WITH
MULTIPLE TARGET CELL POPULATIONS**

SHAOLI WANG

School of Mathematics and Statistics
Henan University
Kaifeng 475001, Henan, China

JIANHONG WU

Centre for Disease Modelling
York University
Toronto, Ontario, M3J 1P3, Canada

LIBIN RONG

Department of Mathematics and Statistics
Oakland University
Rochester, MI 48309, USA

(Communicated by Xingfu Zou)

ABSTRACT. Some viruses can infect different classes of cells. The age of infection can affect the dynamics of infected cells and viral production. Here we develop a viral dynamic model with the age of infection and multiple target cell populations. Using the methods of semigroup and Lyapunov function, we study the global asymptotic property of the steady states of the model. The results show that when the basic reproductive number falls below 1, the infection is predicted to die out. When the basic reproductive number exceeds 1, there exists a unique infected steady state which is globally asymptotically stable. The model can be extended to study virus dynamics with multiple compartments or coinfection by multiple types of viruses. We also show that under some scenarios the age-structured model can be reduced to an ordinary differential equation system with or without time delays.

1. Introduction. Mathematical modeling has been proven to be valuable in understanding virus infection and immune responses. Models and analysis can provide important insights into the dynamics of viral load in vivo and offer helpful suggestions for clinical treatment. Many of the models are based on a differential equation system, which describes the coupled changes in target cells, infected cells, and free virus particles through time in a single compartment (i.e. the blood) of an infected

2010 *Mathematics Subject Classification.* Primary: 37B25, 92D25; Secondary: 35A24, 35M30.

Key words and phrases. Age structure, global asymptotic property, Lyapunov function, semigroup, multiple compartments.

This work was finished when S. Wang visited York University. Wang is supported by NSFC (No.11326200), Foundation of He'nan Educational Committee (No.15A110015, No.15A110018), and The Grant of China Scholarship Council (No.201408410018). L. Rong is partially supported by the NSF grant DMS-1349939.

individual. An example is the application of models to hepatitis B virus (HBV) infection. Persistent infection with HBV is a major health problem worldwide. HBV infection can lead to cirrhosis and primary hepatocellular carcinoma [2,42]. Chronic HBV infection is usually the result of exposure to virus early in life, leading to viral persistence in the absence of strong antibody or cellular immune responses [8]. Treatment of HBV carriers aims to either inhibit viral replication or enhance immunological responses against the virus, or both [26]. Based on the clinical experiment of chronic HBV carriers treated with various doses of lamivudine, Nowak and Bangham [23] used a basic mathematical model to study HBV dynamics. Nowak et al. [24] provided a quantitative understanding of HBV replication dynamics in vivo, estimated the turnover rates of infected cells and virus, and suggested the optimal timing of drug treatment and immunotherapy in chronic HBV infection. Some other within-host virus dynamics models have also been developed to study HBV [33–35], HIV [17, 18, 46], and hepatitis C virus (HCV) infection [27, 29].

The age structure of population has been widely investigated in epidemiological models [3, 20, 37, 41]. Because of its flexibility in modeling viral production and mortality of infected cells, age structure of infected cells has also been incorporated into within-host virus infection models [9, 22, 28, 39, 40]. For example, Nelson et al. [22] developed and analyzed an age-structured HIV model that allowed the variation in the production rate of virus and the death rate of infected CD4+ T cells. For some special functions, they performed a local stability analysis of the nontrivial equilibrium solution. They used numerical methods to show that the time to reach peak viral levels in the blood depends on both initial conditions and the way in which viral production ramps up. Because the age structure of infection allows the incorporation of different classes of antiretroviral drugs that target different stages of viral lifecycle, Rong et al. [28] used the age-structured model to compare the treatment effectiveness of administering different drugs [28]. They conducted analysis of the model under treatment for general functions of the death rate of infected cells and viral production rate. Using an age-structured model, Gilchrist et al. [9] also explored how an infected cell's viral production rate can affect the relative fitness of a virus within a host. They performed an invasion analysis to discuss the strategy for achieving the maximum relative viral fitness. Recently Wang et al. [39] analyzed an age-structured HIV model with both virus-to-cell infection and cell-to-cell transmission.

The global stability of age-structured within-host models is the focus of a few recent studies. Huang et al. [12] studied the global asymptotic behavior of an age-structured HIV infection model. Browne et al. [5] studied the within-host viral infection with an explicit age-since-infection structure of infected cells. Browne [4] also considered the global stability of within-host viral infection with multiple strains. Shen et al. analyzed a model that links the between-host and within-host dynamics of HIV infection [30]. More age-structured within-host models can be found in the references [1, 16, 29, 36].

Viruses can infect different populations of target cells. For example, HIV mainly infect CD4+ T cells. However, other cells such as macrophages [13] and dendritic cells [25] are also known to be susceptible to HIV infection. Similar to HIV infection, HCV can also infect different classes of cells. HCV replicates mainly in the hepatocytes of the liver but the virus can also replicate in peripheral blood mononuclear cells [7]. Thus, multi-compartment mathematical models are needed to study virus infection in different populations of cells [38]. In this note, we will study a

within-host virus dynamics model including the age of infection and multiple populations of target cells. We will prove that the solution of the system is positive and bounded. Using the methods semigroup and Lyapunov function, we will investigate the global asymptotic property of the infected steady state of the model. Under some special scenarios, we will show that the age of infection model is equivalent to an ordinary differential equation system with or without time delays.

2. Model description. We consider a general age-structured within-host virus dynamics model that includes multiple classes of target cells. The population is divided into $2n+1$ classes: uninfected cells, T_j , infected cells, i_j , where $j = 1, 2, \dots, n$, and free virus, V . The model is given by the following system:

$$\begin{cases} \frac{dT_j(t)}{dt} = s_j - d_j T_j(t) - \frac{k_j T_j(t)V(t)}{1 + \alpha_j V(t)}, \\ \frac{\partial i_j(a, t)}{\partial t} + \frac{\partial i_j(a, t)}{\partial a} = -\delta_j(a) i_j(a, t), \\ \frac{dV(t)}{dt} = \sum_{j=1}^n \int_0^\infty p_j(a) i_j(a, t) da - cV(t), \end{cases} \tag{2.1}$$

for $t > 0$, with initial conditions

$$T_j(0) = T_j^0 \geq 0, \quad i_j(a, 0) = i_j^0(a), \quad j = 1, 2, \dots, n; \quad V(0) = V^0 \geq 0, \tag{2.2}$$

and boundary conditions

$$i_j(0, t) = \frac{k_j T_j(t)V(t)}{1 + \alpha_j V(t)}. \tag{2.3}$$

For each class (denoted by the subscript j , $j=1, 2, \dots, n$) of target cells, T represents the population of uninfected cells, $i(a, t)$ denotes the population of infected cells with the infection age a at time t , and V is the population of free virus. The parameter s_j is the production rate of uninfected cells and d_j is the death rate of uninfected cells. Here we use a saturation-dependent functional response ($k_j T_j / (1 + \alpha_j V)$ with $\alpha > 0$) to describe the infection of cells by virus. A similar function has been used in other within-host models [31, 36, 43, 44]. The distribution function $i_j^0(a) \in L^1_+((0, +\infty), \mathcal{R})$ is the initial condition. The function $\delta_j(a)$ is the age-dependent per capita death rate of infected cells and $p_j(a)$ is the viral production rate of an infected cell with age a . The parameter c is the viral clearance rate.

An example of the death rate of infected cells can be chosen to be the same as that in [22], which is given as follows:

$$\delta_j(a) = \begin{cases} \delta_j^0, & a < a_1, \\ \delta_j^0 + \delta_j^m (1 - e^{-\gamma(a-a_1)}), & a \geq a_1, \end{cases} \tag{2.4}$$

where a_1 is the age at which infected cells express sufficient viral genome on the surface and are susceptible to killing by immune cells. Thus, the death rate of infected cells increases from δ_j^0 at age a_1 to the maximum value $\delta_j^0 + \delta_j^m$.

Integrating the second equation in (2.1) along the characteristic line $t - a = \text{constant}$, we get the following formula

$$i_j(a, t) = \begin{cases} B_j(t - a)\sigma_j(a), & \text{for } a < t, \\ i_j(a - t, 0) \frac{\sigma_j(a)}{\sigma_j(a - t)}, & \text{for } a \geq t, \end{cases} \tag{2.5}$$

where

$$B_j(t) = \frac{k_j T_j(t) V(t)}{1 + \alpha_j V(t)}$$

and

$$\sigma_j(a) = \exp\left(-\int_0^a \delta_j(\theta) d\theta\right).$$

Using the above solution, model (2.1) can be written as the following system.

$$\begin{cases} \frac{dT_j(t)}{dt} = s_j - d_j T_j(t) - \frac{k_j T_j(t) V(t)}{1 + \alpha_j V(t)}, \\ \frac{dV(t)}{dt} = \sum_{j=1}^n \left(\int_0^t p_j(a) \sigma_j(a) B_j(t-a) da + \widetilde{F}_j(t) \right) - cV(t), \end{cases} \quad (2.6)$$

where

$$\widetilde{F}_j(t) = \int_t^\infty p_j(a) i_j^0(a-t) \frac{\sigma_j(a)}{\sigma_j(a-t)} da.$$

It is clear that $\widetilde{F}_j(t) \rightarrow 0$ as $t \rightarrow \infty$, $i = 1, 2, \dots, n$.

For cells with age-dependent viral production and death rates, we define

$$N_j = \int_0^\infty p_j(a) \sigma_j(a) da.$$

N_j defines the total number of virions produced by the infected cell of the j -th class in its life span, which is called the viral burst size of the j -th class. The basic reproductive number is given by

$$R_0 = \sum_{j=1}^n \frac{N_j s_j k_j}{cd_j},$$

which represents the total number of newly infected cells produced by one infected cell during its lifetime in a fully susceptible environment (i.e. assuming all cells are susceptible).

3. Integrated semigroup formulation and equilibria. In order to take into account the boundary condition, we expand the state space. Denote

$$\mathcal{M} = \mathcal{R} \times L^1((0, +\infty), \mathcal{R}), \mathcal{M}_+ = \mathcal{R}_+ \times L^1((0, +\infty), \mathcal{R}),$$

$$\mathcal{N} = \mathcal{R} \times \{0\} \times W^{1,1}((0, +\infty), \mathcal{R}),$$

$$\mathcal{P} = \mathcal{R} \times \{0\} \times L^1((0, +\infty), \mathcal{R}), \mathcal{P}_+ = \mathcal{R}_+ \times \{0\} \times L^1((0, +\infty), \mathcal{R}),$$

where $W^{1,1}$ is a Sobolev space. Let

$$\mathcal{X} = \left(\prod_1^n \mathcal{M} \right) \times \mathcal{R}, \mathcal{X}_+ = \left(\prod_1^n \mathcal{M}_+ \right) \times \mathcal{R}_+$$

and consider the linear operator $\mathcal{A} : \text{Dom}(\mathcal{A}) \subset \mathcal{X} \rightarrow \mathcal{X}$ defined by

$$\mathcal{A} \begin{pmatrix} T_1 \\ \begin{pmatrix} 0 \\ i_1 \end{pmatrix} \\ \vdots \\ T_n \\ \begin{pmatrix} 0 \\ i_n \end{pmatrix} \\ V \end{pmatrix} = \begin{pmatrix} -d_1 T_1 \\ \begin{pmatrix} i_1(0) \\ -i_1' - \delta(a)i_1 \end{pmatrix} \\ \vdots \\ -d_n T_n \\ \begin{pmatrix} i_n(0) \\ -i_n' - \delta(a)i_n \end{pmatrix} \\ -cV \end{pmatrix},$$

with

$$Dom(\mathcal{A}) = \left(\prod_1^n \mathcal{P} \right) \times \mathcal{R}.$$

Then $\overline{Dom(\mathcal{A})} = \left(\prod_1^n \mathcal{N} \right) \times \mathcal{R}$ is not dense in \mathcal{X} . We consider a nonlinear map

$\mathcal{F} : \overline{Dom(\mathcal{A})} \rightarrow \mathcal{X}$, which is defined by

$$\mathcal{F} \begin{pmatrix} T_1 \\ \begin{pmatrix} 0 \\ i_1 \end{pmatrix} \\ \vdots \\ T_n \\ \begin{pmatrix} 0 \\ i_n \end{pmatrix} \\ V \end{pmatrix} = \begin{pmatrix} s_1 - \frac{k_1 T_1(t)V(t)}{1+\alpha_1 V(t)} \\ \begin{pmatrix} \psi T_1(t) \\ 0_{L^1} \end{pmatrix} \\ \vdots \\ s_n - \frac{k_n T_n(t)V(t)}{1+\alpha_n V(t)} \\ \begin{pmatrix} \psi T_n(t) \\ 0_{L^1} \end{pmatrix} \\ \int_0^\infty p_n(a) i_n(a, x, t) da \end{pmatrix},$$

and let

$$u(t) = \left(T_1, \begin{pmatrix} 0 \\ i_1(\cdot, t) \end{pmatrix}, \dots, T_n, \begin{pmatrix} 0 \\ i_n(\cdot, t) \end{pmatrix}, V \right)^T.$$

Set

$$\mathcal{X}_0 = \overline{Dom(\mathcal{A})} = \left(\prod_1^n \mathcal{P} \right) \times \mathcal{R}$$

and

$$\mathcal{X}_{0+} = \overline{Dom(\mathcal{A})} \cap \mathcal{X}_+ = \left(\prod_1^n \mathcal{P}_+ \right) \times \mathcal{R}_+.$$

On the basis of the above formulation, system (2.1)~(2.3) can be rewritten as the following abstract Cauchy problem:

$$u(t) = \mathcal{A}u(t) + \mathcal{F}(u(t)), \text{ for } t \geq 0, \text{ with } u(0) = x \in \mathcal{X}_{0+}. \tag{3.1}$$

By applying the results given in Hale [10], Magal [19], Magal and Thieme [21], Thieme [32], Yang et al. [45] and Wang et al. [40, 41] we can show the existence and uniqueness of the semiflow $\{U(t)\}_{t \geq 0}$ on \mathcal{X}_{0+} generated by system (3.1) and further have the following result.

Theorem 3.1. *System (3.1) generates a unique continuous semiflow $\{U(t)\}_{t \geq 0}$ on \mathcal{X}_{0+} that is asymptotically smooth and bounded dissipative. Furthermore, the semiflow $\{U(t)\}_{t \geq 0}$ has a compact global attractor $\mathcal{A} \subset \mathcal{X}_{0+}$.*

Define

$$\mathcal{M}_0 = \left\{ (T_1, i_1(a), \dots, T_n, i_n(a), V)^T \in \mathcal{X}_{0+} \mid V + \sum_{j=1}^n \int_0^\infty i_j(a) da > 0 \right\}$$

and

$$\partial\mathcal{M}_0 = \mathcal{X}_{0+} \setminus \mathcal{M}_0.$$

Following Theorems 4.1 and 4.2 in [45], we can get the following theorems. Here we omit the proofs.

Theorem 3.2. \mathcal{M}_0 and $\partial\mathcal{M}_0$ are both positively invariant under the semiflow $U(t)_{t \geq 0}$ generated by system (3.1) on \mathcal{X}_{0+} . Moreover, the infection-free steady state E_0 of problem (2.1)~(2.3) is globally asymptotically stable for the semiflow $U(t)_{t \geq 0}$ restricted to $\partial\mathcal{M}_0$.

Theorem 3.3. Assuming $R_0 \leq 1$, the semiflow $U(t)_{t \geq 0}$ generated by system (3.1) is uniformly persistent with respect to the pair $(\partial\mathcal{M}_0, \mathcal{M}_0)$; that is, there exists $\epsilon > 0$, such that for each $y \in \mathcal{M}_0$,

$$\liminf_{t \rightarrow +\infty} d(U(t)y, \partial\mathcal{M}_0) \geq \epsilon.$$

Furthermore, there exists a compact subset $\mathcal{A}_0 \subset \mathcal{M}_0$ which is a global attractor for $U(t)_{t \geq 0}$ in \mathcal{M}_0 .

4. The global results of steady states. In this section, we focus on the global asymptotic properties of the steady states of system (2.1)~(2.3). Generally, it can be challenging to obtain the global properties of a model with saturation response of the infection rate, especially for the model with age structure.

Theorem 4.1. System (2.1) always has an infection-free steady state $E^0(T_{10}, 0, \dots, T_{n0}, 0, 0)$. When the basic reproductive ratio is greater than 1, system (2.1) has a unique positive infected steady state $E^*(T_1^*, i_1^*(a), \dots, T_n^*, i_n^*(a), V^*)$.

Proof. It is clear that there always exists an infection-free steady state $E^0(T_{10}, 0, \dots, T_{n0}, 0, 0)$ for system (2.1). To obtain the infected steady state $E^*(T_1^*, i_1^*(a), \dots, T_n^*, i_n^*(a), V^*)$, we solve the following algebraic equations.

$$\begin{cases} s_j - d_j T_j^* - \frac{k_j T_j^* V^*}{1 + \alpha_j V^*} = 0 \\ i_j^*(a) = \frac{k_j T_j^* V^*}{1 + \alpha_j V^*} \sigma_j(a) \\ \sum_{j=1}^n \frac{N_j k_j T_j^*}{1 + \alpha_j V^*} = c, \end{cases} \quad (4.1)$$

From the first equation of (4.1), we have

$$T_j^* = \frac{s_j}{d_j + \frac{k_j V^*}{1 + \alpha_j V^*}}.$$

Substituting into the last equation of (3.2), we get

$$\sum_{j=1}^n \frac{N_j k_j s_j}{d_j + (k_j + d_j \alpha_j) V^*} = c.$$

Let

$$F(V) = \sum_{j=1}^n \frac{N_j k_j s_j}{d_j + (k_j + d_j \alpha_j)V} - c.$$

On one hand, $F(V)$ is continuous and monotonically decreasing for $V \in [0, +\infty)$. We also have

$$F(0) = \sum_{j=1}^n \frac{N_j k_j s_j}{d_j} - c = \sum_{j=1}^n \frac{N_j k_j s_j}{d_j} \left(1 - \frac{1}{R_0}\right) > 0$$

for $R_0 > 1$. On the other hand,

$$F(\infty) = 0 - c < 0.$$

Therefore, equation $F(V) = 0$ has one positive solution V^* . Thus, when $R_0 > 1$, systems (2.1) has a unique positive infected steady state E^* . \square

Let $\tilde{E}(\tilde{T}_1, \tilde{i}_1(a), \tilde{T}_2, \tilde{i}_2(a), \dots, \tilde{T}_n, \tilde{i}_n(a), \tilde{V})$ be any arbitrary steady state of system (2.1)~(2.3). The linearized system of (2.1)~(2.3) is

$$\begin{cases} (\lambda + d_j + \frac{k_j \tilde{V}}{1 + \alpha_j \tilde{V}})T_j + \frac{k_j \tilde{T}_j}{(1 + \alpha_j \tilde{V})^2}V = 0, \\ \frac{di_j(a)}{da} = -(\lambda + \delta_j(a))i_j(a), \\ i_j(0) = \frac{k_j \tilde{V}}{1 + \alpha_j \tilde{V}}T_j + \frac{k_j \tilde{T}_j}{(1 + \alpha_j \tilde{V})^2}V, \\ (\lambda + c)V - \sum_{j=1}^n \int_0^\infty p_j(a)i_j(a)da = 0. \end{cases} \tag{4.2}$$

Solving the second equation of (4.2), we have

$$i_j(a) = \left(\frac{k_j \tilde{V}}{1 + \alpha_j \tilde{V}}T_j + \frac{k_j \tilde{T}_j}{(1 + \alpha_j \tilde{V})^2}V \right) \sigma_j(a) e^{-\lambda a}. \tag{4.3}$$

Substituting equation (4.3) into (4.2), we have

$$\begin{cases} (\lambda + d_1 + \frac{k_1 \tilde{V}}{1 + \alpha_1 \tilde{V}})T_1 + \frac{k_1 \tilde{T}_1}{(1 + \alpha_1 \tilde{V})^2}V = 0, \\ (\lambda + d_2 + \frac{k_2 \tilde{V}}{1 + \alpha_2 \tilde{V}})T_2 + \frac{k_2 \tilde{T}_2}{(1 + \alpha_2 \tilde{V})^2}V = 0, \\ \dots \\ (\lambda + d_n + \frac{k_n \tilde{V}}{1 + \alpha_n \tilde{V}})T_n + \frac{k_n \tilde{T}_n}{(1 + \alpha_n \tilde{V})^2}V = 0, \\ \left(\lambda + c - \sum_{j=1}^n \frac{k_j \tilde{T}_j}{(1 + \alpha_j \tilde{V})^2}N_j(\lambda) \right)V - \sum_{j=1}^n \frac{k_j \tilde{V}}{1 + \alpha_j \tilde{V}}N_j(\lambda)T_j = 0. \end{cases}$$

For the infection-free steady state E_0 , the characteristic equation of the linearized system of (2.1)~(2.3) is

$$\left(\prod_{j=1}^n (\lambda + d_j) \right) \left(\lambda + c - \sum_{j=1}^n k_j T_{j0} N_j(\lambda) \right) = 0.$$

Let

$$F(\lambda) = \lambda + c - \sum_{j=1}^n k_j T_{j0} N_j(\lambda).$$

Then

$$F'(\lambda) > 0$$

and

$$F(0) = c(1 - R_0) > 0$$

for $R_0 \leq 1$. Therefore, all the eigenvalues of the infection-free steady state E_0 are negative.

For $R_0 > 1$, we have

$$F(0) = c(1 - R_0) < 0, \lim_{t \rightarrow +\infty} F(\lambda) = +\infty.$$

Thus, $F(\lambda) = 0$ has a positive root and the infection-free steady state E_0 is unstable. We summarize in the following results.

Lemma 4.1. *If $R_0 \leq 1$, then the infection-free steady state E_0 is locally asymptotically stable. While $R_0 > 1$, E_0 is unstable.*

Theorem 4.2. *If $R_0 \leq 1$, then the infection-free steady state E_0 of model (2.1)~(2.3) is globally asymptotically stable.*

Proof. From the equations of target cells in system (2.1), we obtain

$$\lim_{t \rightarrow +\infty} T_j(t) \leq \frac{s_j}{d_j}, \quad j = 1, \dots, n.$$

One can choose $\varepsilon > 0$ small enough such that there exists t_1 such that $T_j(t) \leq \frac{s_j}{d_j} + \varepsilon$ for all $t \geq t_1$.

$$\begin{cases} \frac{dV(t)}{dt} = \sum_{j=1}^n \int_0^\infty p_j(a) i_j(a, t) da - cV(t), t > 0, \\ V(0) = V^0 \geq 0. \end{cases} \quad (4.4)$$

From (4.4), we obtain the following inequality.

$$\frac{dV(t)}{dt} \leq \sum_{j=1}^n N_j k_j \left(\frac{s_j}{d_j} + \varepsilon \right) - cV(t), t > 0, \quad (4.5)$$

where ε is chosen as before. Considering $R_0 \leq 1$, from (4.5), we have

$$\lim_{t \rightarrow +\infty} \sup V(t) = 0.$$

By comparison, it follows that

$$\lim_{t \rightarrow +\infty} V(t) = 0.$$

Therefore, for $\varepsilon > 0$ sufficiently small there exists a $t_2 > 0$ such that $0 < V(t) < \varepsilon$ for $t \geq t_2$.

Again from the equations of target cells in system (2.1), we can get

$$\frac{dT_j(t)}{dt} = s_j - d_j T_j(t) - \frac{k_j T_j(t) V(t)}{1 + \alpha_j V(t)} \geq s_j - d_j T_j(t) - k_j \varepsilon T_j(t), \quad t > t_2,$$

which, together with the arbitrariness of $\varepsilon > 0$, yields that

$$\lim_{t \rightarrow +\infty} T_j(t) \geq \frac{s_j}{d_j}.$$

Thus,

$$\lim_{t \rightarrow +\infty} T_j(t) = \frac{s_j}{d_j}.$$

Combining with Lemma 4.1, we can conclude that the infection-free steady state E_0 of model (2.1)~(2.3) is a globally asymptotically stable. \square

Theorem 4.3. *When $R_0 > 1$, the infected steady state E^* of model (2.1)~(2.3) is globally asymptotically stable.*

Proof. First, we define a positive function as used in ref. [12]

$$\beta_j(a) = \int_a^\infty p_j(\epsilon) e^{-\int_a^\epsilon \delta_j(\eta) d\eta} d\epsilon.$$

Note that $\beta_j(a) > 0$ for $0 \leq a < +\infty$, and $\beta_j(0) = N_j$. Similar to the discussion in [12], we know that $\beta_j(a)$ is bounded and $\beta_j'(a) = \delta_j(a)\beta_j(a) - p_j(a)$.

We consider the following Lyapunov function

$$\begin{aligned} W(t) = & N_1 \left(T_1(t) - T_1^* - T_1^* \ln \frac{T_1(t)}{T_1^*} \right) \\ & + \int_0^{+\infty} \beta_1(a) i_1^*(a) \left(\frac{i_1(a,t)}{i_1^*(a)} - 1 - \ln \frac{i_1(a,t)}{i_1^*(a)} \right) da \\ & + \sum_{j=2, \dots, n} N_j \left(T_j(t) - T_j^* - T_j^* \ln \frac{T_j(t)}{T_j^*} \right) \\ & + \sum_{j=2, \dots, n} \int_0^\infty \beta_j(a) i_j^*(a) \left(\frac{i_j(a,t)}{i_j^*(a)} - 1 - \ln \frac{i_j(a,t)}{i_j^*(a)} \right) da \\ & + \left(V(t) - V^* - V^* \ln \frac{V(t)}{V^*} \right). \end{aligned}$$

It is clear to see that W is nonnegative and the point E^* is the global minimum point. Calculating the time derivative of W along the solution of system (2.1)~(2.3), we obtain

$$\begin{aligned} \frac{dW(t)}{dt} = & N_1 \left(1 - \frac{T_1^*}{T_1(t)} \right) \left(s_1 - d_1 T_1(t) - \frac{k_1 T_1(t) V(t)}{1 + \alpha_1 V(t)} \right) \\ & + \int_0^{+\infty} \beta_1(a) i_1^*(a) \frac{\partial}{\partial t} \left(\frac{i_1(a,t)}{i_1^*(a)} - 1 - \ln \frac{i_1(a,t)}{i_1^*(a)} \right) da \\ & + \sum_{j=2, \dots, n} N_j \left(1 - \frac{T_j^*}{T_j(t)} \right) \left(s_j - d_j T_j(t) - \frac{k_j T_j(t) V(t)}{1 + \alpha_j V(t)} \right) \\ & + \sum_{j=2, \dots, n} \int_0^\infty \beta_j(a) i_j^*(a) \frac{\partial}{\partial t} \left(\frac{i_j(a,t)}{i_j^*(a)} - 1 - \ln \frac{i_j(a,t)}{i_j^*(a)} \right) da \\ & + \left(1 - \frac{V^*}{V(t)} \right) \left(\sum_{j=1}^n \int_0^\infty p_j(a) i_j(a,t) da - cV(t) \right). \end{aligned}$$

It follows from $s_j = d_j T_j^* + \frac{k_j T_j^* V^*}{1 + \alpha_j V^*}$ and $\sum_{j=1}^n \frac{N_j k_j T_j^*}{1 + \alpha_j V^*} = c$ that

$$\frac{dW(t)}{dt} = \text{term}\textcircled{1} + \text{term}\textcircled{2} + \text{term}\textcircled{3},$$

where

$$\text{term}\textcircled{1} = N_1 \left[\left(1 - \frac{T_1^*}{T_1(t)} \right) d_1 (T_1^* - T_1(t)) + \frac{k_1 T_1^* V^*}{1 + \alpha_1 V^*} \right]$$

$$\begin{aligned}
& - \frac{k_1 T_1(t) V(t)}{1 + \alpha_1 V(t)} + \frac{k_1 T_1^* V(t)}{1 + \alpha_1 V} - \frac{T_1^*}{T_1(t)} \frac{k_1 T_1^* V^*}{1 + \alpha_1 V^*} \Big] \\
& + \int_0^\infty \beta_1(a) \left(1 - \frac{i_1^*(a)}{i_1(a, t)}\right) \frac{\partial i_1(a, t)}{\partial t} da, \\
\text{term} \textcircled{2} & = \sum_{j=2, \dots, n} N_j \left[\left(1 - \frac{T_j^*}{T_j(t)}\right) d_j (T_j^* - T_j(t)) + \frac{k_j T_j^* V^*}{1 + \alpha_j V^*} \right. \\
& \quad \left. - \frac{k_j T_j(t) V(t)}{1 + \alpha_j V(t)} + \frac{k_j T_j^* V(t)}{1 + \alpha_j V} - \frac{T_j^*}{T_j(t)} \frac{k_j T_j^* V^*}{1 + \alpha_j V^*} \right] \\
& + \sum_{j=2, \dots, n} \int_0^\infty \beta_j(a) \left(1 - \frac{i_j^*(a)}{i_j(a, t)}\right) \frac{\partial i_j(a, t)}{\partial t} da \\
& + \int_0^\infty p_1(a) i_1(a, t) da - \frac{V^*}{V(t)} \int_0^\infty p_1(a) i_1(a, t) da, \\
\text{term} \textcircled{3} & = \frac{N_1 k_1 T_1^* V^*}{1 + \alpha_1 V^*} - \frac{N_1 k_1 T_1^* V(t)}{1 + \alpha_1 V^*} + \sum_{j=2, \dots, n} \int_0^\infty p_j(a) i_j(a, t) da \\
& - \sum_{j=2, \dots, n} \frac{V^*}{V(t)} \int_0^\infty p_j(a) i_j(a, t) da \\
& + \sum_{j=2, \dots, n} \left[\frac{N_j}{N_1} \frac{k_j T_j^* V^*}{1 + \alpha_j V^*} - \frac{N_j}{N_1} \frac{k_j T_j^* V(t)}{1 + \alpha_j V^*} \right].
\end{aligned}$$

We further obtain that

$$\begin{aligned}
\frac{dW(t)}{dt} & = -d_1 N_1 T_1^* \left(2 - \frac{T_1(t)}{T_1^*} - \frac{T_1^*}{T_1(t)}\right) \\
& - \beta_1(a) i_1^*(a) \left(\frac{i_1(a, t)}{i_1^*(a)} - 1 - \ln \frac{i_1(a, t)}{i_1^*(a)}\right) \Big|_{a=\infty} \\
& - \frac{N_1 k_1 T_1^* V^*}{1 + \alpha_1 V^*} \left[\frac{T_1^*}{T_1(t)} - 1 + \frac{V(t)}{V^*} - \frac{V(t)}{V^*} \frac{1 + \alpha_1 V^*}{1 + \alpha_1 V(t)} \right. \\
& \quad \left. + \ln \frac{T_1(t) V(t) (1 + \alpha_1 V^*)}{T_1^* V^* (1 + \alpha_1 V(t))} \right] \\
& - \int_0^\infty p_1(a) i_1^*(a) \left(\frac{V^* i_1(a, t)}{V i_1^*(a)} - 1 - \ln \frac{i_1(a, t)}{i_1^*(a)}\right) da \\
& - \sum_{j=2, \dots, n} N_j d_j T_j^* \left(2 - \frac{T_j(t)}{T_j^*} - \frac{T_j^*}{T_j(t)}\right) \\
& - \sum_{j=2, \dots, n} \beta_j(a) i_j^*(a) \left(\frac{i_j(a, t)}{i_j^*(a)} - 1 - \ln \frac{i_j(a, t)}{i_j^*(a)}\right) \Big|_{a=\infty} \\
& - \sum_{j=2, \dots, n} \frac{N_j k_j T_j^* V^*}{1 + \alpha_1 V^*} \left[\frac{T_j^*}{T_j(t)} - 1 + \frac{V(t)}{V^*} \right]
\end{aligned}$$

$$\begin{aligned}
 & - \frac{V(t)}{V^*} \frac{1 + \alpha_j V^*}{1 + \alpha_j V(t)} + \ln \frac{T_j(t)V(t)(1 + \alpha_j V^*)}{T_j^* V^* (1 + \alpha_j V(t))} \Big] \\
 & - \sum_{j=2, \dots, n} \int_0^\infty p_j(a) i_j^*(a) \left(\frac{V^* i_j(a, t)}{V i_j^*(a)} - 1 - \ln \frac{i_j(a, t)}{i_j^*(a)} \right) da.
 \end{aligned}$$

Because

$$1 + \frac{V(t)}{V^*} - \frac{1 + \alpha_j V(t)}{1 + \alpha_j V^*} - \frac{V(t)}{V^*} \frac{1 + \alpha_j V^*}{1 + \alpha_j V(t)} = \frac{(V(t) - V^*)^2}{V^*(1 + \alpha_j V^*)(1 + \alpha_j V(t))}$$

and

$$\ln \frac{T_j^* V^* (1 + \alpha_j V(t))}{T_j(t)V(t)(1 + \alpha_j V^*)} + \ln \frac{i_j(a, t)}{i_j^*(a)} = \ln \frac{T_j^*}{T_j(t)} + \ln \frac{1 + \alpha_j V(t)}{1 + \alpha_j V^*} + \ln \frac{i_j(a, t)V^*}{i_j^*(a)V(t)},$$

we have

$$\begin{aligned}
 & \frac{dW(t)}{dt} \\
 & = -d_1 N_1 T_1^* \left(2 - \frac{T_1(t)}{T_1^*} - \frac{T_1^*}{T_1(t)} \right) \\
 & - \beta_1(a) i_1^*(a) \left(\frac{i_1(a, t)}{i_1^*(a)} - 1 - \ln \frac{i_1(a, t)}{i_1^*(a)} \right) \Big|_{a=\infty} \\
 & - \frac{N_1 k_1 T_1^* V^*}{1 + \alpha_1 V^*} \left[\left(\frac{T_1^*}{T_1(t)} - 1 - \ln \frac{T_1^*}{T_1(t)} \right) + \left(\frac{1 + \alpha_1 V(t)}{1 + \alpha_1 V^*} - 1 - \ln \frac{1 + \alpha_1 V(t)}{1 + \alpha_1 V^*} \right) \right. \\
 & \left. + \frac{(V(t) - V^*)^2}{V^*(1 + \alpha_1 V^*)(1 + \alpha_1 V(t))} \right] \\
 & - \int_0^\infty p_1(a) i_1^*(a) \left(\frac{V^* i_1(a, t)}{V(t) i_1^*(a)} - 1 - \ln \frac{V^* i_1(a, t)}{V(t) i_1^*(a)} \right) da \\
 & - \sum_{j=2, \dots, n} N_j d_j T_j^* \left(2 - \frac{T_j(t)}{T_j^*} - \frac{T_j^*}{T_j(t)} \right) \\
 & - \sum_{j=2, \dots, n} \beta_j(a) i_j^*(a) \left(\frac{i_j(a, t)}{i_j^*(a)} - 1 - \ln \frac{i_j(a, t)}{i_j^*(a)} \right) \Big|_{a=\infty} \\
 & - \sum_{j=2, \dots, n} \frac{N_j k_j T_j^* V^*}{1 + \alpha_1 V^*} \left[\left(\frac{T_j^*}{T_j(t)} - 1 - \ln \frac{T_j^*}{T_j(t)} \right) \right. \\
 & \left. + \left(\frac{1 + \alpha_j V(t)}{1 + \alpha_j V^*} - 1 - \ln \frac{1 + \alpha_j V(t)}{1 + \alpha_j V^*} \right) \right. \\
 & \left. + \frac{N_j k_j T_j^*}{1 + \alpha_1 V^*} \frac{(V(t) - V^*)^2}{(1 + \alpha_j V^*)(1 + \alpha_j V(t))} \right] \\
 & - \sum_{j=2, \dots, n} \int_0^\infty p_j(a) i_j^*(a) \left(\frac{V^* i_j(a, t)}{V(t) i_j^*(a)} - 1 - \ln \frac{V^* i_j(a, t)}{V(t) i_j^*(a)} \right) da.
 \end{aligned}$$

Because the arithmetical mean is greater than or equal to the geometrical mean, we know that $2 - \frac{T_j(t)}{T_j^*} - \frac{T_j^*}{T_j(t)}$ is less than or equal to zero. It follows that $\frac{dW}{dt} = 0$ if and only if $T_j(t) = T_j^*$, $i_j(a, t) = i_j^*(a)$, and $V(t) = V^*$. Hence, every solution of system (2.1) converges to E^* , which means that the infected steady state is globally asymptotically stable from the LaSalle's invariance principle. \square

5. Related models. In this section, we show that under some special cases the age of infection model (2.1)~(2.3) can be reduced to an ordinary differential equation (ODE) system with or without time delays.

Case I. Assume that $\delta_j(a) = \delta_j$, $p_j(a) = p_j$, where δ_j and p_j are positive constants. Model (2.1) can be rewritten as

$$\begin{cases} \frac{dT_j(t)}{dt} = s_j - d_j T_j(t) - \frac{k_j T_j(t) V(t)}{1 + \alpha_j V(t)}, \\ \frac{\partial i_j(a, t)}{\partial t} + \frac{\partial i_j(a, t)}{\partial a} = -\delta_j i_j(a, t), \\ i_j(0, t) = \frac{k_j T_j(t) V(t)}{1 + \alpha_j V(t)}, \\ \frac{dV(t)}{dt} = \sum_{j=1}^n p_j \int_0^\infty i_j(a, t) da - cV(t). \end{cases} \quad (5.1)$$

We further assume that in this case t is larger than all possible infection ages, and consequently $i_j(a, t)$ is expressed by the first half of (2.5), that is,

$$i_j(a, t) = i_j(0, t - a) \exp\left(-\int_0^a \delta_j(\theta) d\theta\right) = i_j(0, t - a) e^{-\delta_j a} \text{ for } a < t.$$

Setting

$$I_j(t) = \int_0^\infty i_j(a, t) da, \quad (5.2)$$

which represents the total number of infected cells in the j th class at time t , we have

$$\begin{aligned} \frac{dI_j(t)}{dt} &= \int_0^\infty \frac{\partial i_j(a, t)}{\partial t} da = -\int_0^\infty \left(\frac{\partial i_j(a, t)}{\partial a} + \delta_j i_j(a, t)\right) da \\ &= -i_j(a, t)|_{a=0}^{a=\infty} - \delta_j \int_0^\infty i_j(a, t) da. \end{aligned}$$

From the boundary condition, one can see that $i_j(0, t) = \frac{k_j V(t) T_j(t)}{1 + \alpha_j V(t)}$. Since $T_j(t)$ and $V(t)$ are bounded on $[0, +\infty)$, it can be concluded that

$$\lim_{a \rightarrow +\infty} i_j(a, t) = \lim_{a \rightarrow +\infty} i_j(0, t - a) e^{-\delta_j a} = \lim_{a \rightarrow +\infty} e^{-\delta_j a} \frac{k_j V(t) T_j(t)}{1 + \alpha_j V(t)} = 0.$$

Hence,

$$\frac{dI_j(t)}{dt} = \frac{k_j V(t) T_j(t)}{1 + \alpha_j V(t)} - \delta_j I_j(t).$$

Thus, model (5.1) is equivalent to a standard ODE model with multiple target cell populations, given by

$$\begin{cases} \frac{dT_j(t)}{dt} = s_j - d_j T_j(t) - \frac{k_j T_j(t) V(t)}{1 + \alpha_j V(t)}, \\ \frac{dI_j(a, t)}{dt} = \frac{k_j V(t) T_j(t)}{1 + \alpha_j V(t)} - \delta_j I_j(a, t), \\ \frac{dV(t)}{dt} = \sum_{j=1}^n p_j I_j(t) - cV(t). \end{cases} \tag{5.3}$$

Note that in the above ODE model, the viral burst size is $N_j = p_j/\delta_j$.

Case II. Assume that it takes time τ for virus to enter into the target cell, and that there is a time delay ω ($\omega > \tau$) between cell infection and viral production. The death rate of infected cells and the viral production rate become

$$\delta_j(a) = \begin{cases} \delta'_j, & a \geq \tau, \\ 0, & 0 \leq a < \tau, \end{cases} \tag{5.4}$$

and

$$p_j(a) = \begin{cases} p'_j, & a \geq \omega, \\ 0, & 0 \leq a < \omega. \end{cases} \tag{5.5}$$

Note that $i_j(\tau, t) = e^{-\tau\delta'_j} i(0, t - \tau)$. We have

$$\frac{dI_j(t)}{dt} = e^{-\tau\delta'_j} \frac{k_j V(t - \tau) T_j(t - \tau)}{1 + \alpha_j V(t - \tau)} - \delta'_j I_j(t).$$

Using function (5.5) we have

$$\begin{aligned} \int_0^\infty p_j(a) i_j(a, t) da &= p'_j \int_\omega^\infty i_j(a, t) da \\ &= p'_j \int_0^\infty i_j(a + \omega, t) da \\ &= p'_j \int_0^\infty e^{-\omega\delta'_j} i_j(a, t - \omega) da \\ &= e^{-\omega\delta'_j} p'_j I_j(t - \omega). \end{aligned}$$

Hence, model (2.1) with the assumptions (5.4) and (5.5) can be reformulated equivalently as the following delay differential equation (DDE) system:

$$\begin{cases} \frac{dT_j(t)}{dt} = s_j - d_j T_j(t) - \frac{k_j T_j(t) V(t)}{1 + \alpha_j V(t)}, \\ \frac{dI_j(a, t)}{dt} = e^{-\tau\delta'_j} \frac{k_j V(t - \tau) T_j(t - \tau)}{1 + \alpha_j V(t - \tau)} - \delta'_j I_1(a, t), \\ \frac{dV(t)}{dt} = \sum_{j=1}^n e^{-\omega\delta'_j} p'_j I_j(t - \omega) - cV(t). \end{cases} \tag{5.6}$$

In the above DDE model, τ and ω are two intracellular delays describing the time required for virus to enter a target cell and for the infected cell to produce virus, respectively.

A special case of model (5.6) is with the assumption $p_j(a) = \bar{p}_j = \text{constant}$. In this case, system (5.6) becomes

$$\begin{cases} \frac{dT_j(t)}{dt} = s_j - d_j T_j(t) - \frac{k_j T_j(t) V(t)}{1 + \alpha_j V(t)}, \\ \frac{dI_j(a, t)}{dt} = e^{-\tau \delta'_j} \frac{k_j V(t - \tau) T_j(t - \tau)}{1 + \alpha_j V(t - \tau)} - \delta'_j I_j(a, t), \\ \frac{dV(t)}{dt} = \sum_{j=1}^n \bar{p}_j I_j(t) - cV(t), \end{cases} \quad (5.7)$$

which contains only one time delay.

6. Summary and Discussion. Viral infection of different classes of target cells is important in understanding the virus dynamics within infected individuals. HIV infection in macrophages may contribute to the early-stage viral transmission, persistence, and virus dissemination throughout the body [6]. Macrophages are resistant to the cytopathic effect of HIV and can produce virus for a longer period of time [14]. Thus, the production of virus by infected macrophages may explain the viral load explosion in the advanced stage of HIV infection. A recent model included the infection of macrophages to explain the three stages of HIV infection [11]. Damage to monocyte/macrophage lineage cells, although less obvious, provides the information to predict the onset of opportunistic infections and progression to AIDS [15]. Infection of peripheral blood mononuclear cells by HCV may explain the high levels of immunological disorders found in chronically infected HCV patients [7].

In this note, we developed and studied a within-host viral dynamic model including multiple populations of target cells and the age of viral infection. The global asymptotic properties for the model are obtained. When the basic reproductive number is below unity, the infection is predicted to die out. When the basic reproductive number exceeds unity, there exists a unique infected steady state which is globally asymptotically stable. This means that the virus is able to establish the infection within the host. With some assumptions the age-structured model can be reduced to an ODE or DDE system. This model can also be extended to study virus dynamics with multiple compartments or coinfection by multiple types/strains of viruses.

The model with multiple populations of target cells can be used to evaluate the relative contribution of viral production from different compartments. This can improve the understanding of viral evolution and disease progression. However, very limited (spatial) data are available for each cell population or compartment. Thus, it is challenging to estimate parameters and verify models. Another limitation of the model is that it cannot account for the long-term HIV dynamics observed in patients on prolonged antiretroviral therapy. Viral infection is predicted to die out if the basic reproductive number is below 1. However, virus can persist for a prolonged period of time even in patients under long-term antiretroviral therapy. HIV latency can be incorporated into the model to study the long-term virus dynamics under therapy.

REFERENCES

- [1] A. Alshorman, C. Samarasinghe, W. Lu and L. Rong, [An HIV model with age-structured latently infected cells](#), *J. Biol. Dyn.*, (2015), 1–24.
- [2] R. P. Beasley, et al., Hepatocellular carcinoma and hepatitis B virus, *Lancet*, **2** (1981), 1129–1133.
- [3] F. Brauer, Z. Shuai and P. van den Driessche, [Dynamics of an age-of-infection cholera model](#), *Math. Biosci. Eng.*, **10** (2013), 1335–1349.

- [4] C. J. Browne, [A multi-strain virus model with infected cell age structure: Application to HIV](#), *Nonlinear Anal. Real World Appl.*, **22** (2015), 354–372.
- [5] C. J. Browne and S. S. Pilyugin, [Global analysis of age-structured within-host virus model](#), *Discrete Contin. Dyn. Syst. Ser. B*, **18** (2013), 1999–2017.
- [6] C. A. Carter and L. S. Ehrlich, [Cell biology of HIV-1 infection of macrophages](#), *Annu. Rev. Microbiol.*, **62** (2008), 425–443.
- [7] I. Castillo, et al., [Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection](#), *Gut.*, **54** (2005), 682–685.
- [8] C. Ferrari, et al., [Cellular immune response to hepatitis B virus encoded antigens in a cute and chronic hepatitis B virus infection](#), *J. Immunol.*, **145** (1990), 3442–3449.
- [9] M. A. Gilchrist, D. Coombs and A. S. Perelson, [Optimizing within-host viral fitness: Infected cell lifespan and virion production rate](#), *J. Theoret. Biol.*, **229** (2004), 281–288.
- [10] J. K. Hale, [Asymptotic Behavior of Dissipative Systems](#), Mathematical Surveys and Monographs, American Mathematical Society, Providence, RI, 1988.
- [11] E. A. Hernandez-Vargas and R. H. Middleton, [Modeling the three stages in HIV infection](#), *J. Theor. Biol.*, **320** (2013), 33–40.
- [12] G. Huang, X. Liu and Y. Takeuchi, [Lyapunov functions and global stability for age-structured HIV infection model](#), *SIAM J. Appl. Math.*, **72** (2012), 25–38.
- [13] S. Koenig, et al, [Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy](#), *Science*, **233** (1986), 1089–1093.
- [14] A. Kumar and G. Herbein, [The macrophage: A therapeutic target in HIV-1 infection](#), *Mol. Cell. Therapies*, **2** (2014), 10pp.
- [15] M. J. Kuroda, [Macrophages: Do they impact AIDS progression more than CD4 T cells?](#) *J. Leukoc. Biol.*, **87** (2010), 569–573.
- [16] X. Lai and X. Zou, [Dynamics of evolutionary competition between budding and lytic viral release strategies](#), *Math. Biosci. Eng.*, **11** (2014), 1091–1113.
- [17] X. Lai and X. Zou, [Modeling HIV-1 virus dynamics with both virus-to-cell Infection and cell-to-cell transmission](#), *SIAM J. Appl. Math.*, **74** (2014), 898–917.
- [18] M. Y. Li and H. Shu, [Global dynamics of an in-host viral model with intracellular delay](#), *Bull. Math. Biol.*, **72** (2010), 1492–1505.
- [19] P. Magal, [Compact attractors for time periodic age-structured population models](#), *Electron J. Differ. Equ.*, **65** (2001), 1–35.
- [20] P. Magal and C. C. McCluskey, [Two-group infection age model including an application to nosocomial infection](#), *SIAM J. Appl. Math.*, **73** (2013), 1058–1095.
- [21] P. Magal and H. R. Thieme, [Eventual compactness for semi ows generated by nonlinear age-structured models](#), *Commun. Pure Appl. Anal.*, **3** (2004), 695–727.
- [22] P. W. Nelson, M. A. Gilchrist, D. Coombs, J. M. Hyman and A. S. Perelson, [An agestructured model of HIV infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells](#), *Math. Biosci. Eng.*, **1** (2004), 267–288.
- [23] M. A. Nowak and C. R. M. Bangham, [Population dynamics of immune response to persistent viruses](#), *Science*, **272** (1996), 74–79.
- [24] M. A. Nowak, et al., [Viral dynamics in hepatitis B virus infection](#), *Proc. Natl. Acad. Sci. USA*, **93** (1996), 4398–4402.
- [25] M. Pope, et al., [Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1](#), *Cell*, **78** (1994), 389–398.
- [26] F. Regenstein, [New approaches to the treatment of chronic viral-hepatitis-B and viral-hepatitis C](#), *Am. J. Med.*, **96** (1994), 47–51.
- [27] L. Rong, H. Dahari, R. M. Ribeiro and A. S. Perelson, [Rapid emergence of protease inhibitor resistance in hepatitis C virus](#), *Sci. Transl. Med.*, **2** (2010), 30ra32.
- [28] L. Rong, Z. Feng and A. S. Perelson, [Mathematical analysis of age-structured HIV-1 dynamics with combination antiviral therapy](#), *SIAM J. Appl. Math.*, **67** (2007), 731–756.
- [29] L. Rong, J. Guedj, H. Dahari, D. Coffield, M. Levi, P. Smith and A. S. Perelson, [Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model](#), *PLoS Comput. Biol.*, **9** (2013), e1002959, 12pp.
- [30] M. Shen, Y. Xiao and L. Rong, [Global stability of an infection-age structured HIV-1 model linking within-host and between-host dynamics](#), *Math. Biosci.*, **263** (2015), 37–50.
- [31] X. Song and A. U. Neumann, [Global stability and periodic solution of the viral dynamics](#), *J. Math. Anal. Appl.*, **329** (2007), 281–297.

- [32] H. R. Thieme, Semiflows generated by Lipschitz perturbations of non-densely defined operators, *Differ. Integral Equ.*, **3** (1990), 1035–1066.
- [33] S. Wang, X. Feng and Y. He, Global asymptotical properties for a diffused HBV infection model with CTL immune response and nonlinear incidence, *Acta Math. Sci. Ser. B Engl. Ed.*, **31** (2011), 1959–1967.
- [34] K. Wang and W. Wang, Propagation of HBV with spatial dependence, *Math. Biosci.*, **210** (2007), 78–95.
- [35] K. Wang, W. Wang and S. Song, Dynamics of an HBV model with diffusion and delay, *J. Theor. Biol.*, **253** (2008), 36–44.
- [36] J. Wang, R. Zhang and T. Kuniya, Mathematical analysis for an age-structured HIV infection model with saturation infection rate, *Electron J. Differ. Equ.*, **33** (2015), 1–19.
- [37] J. Wang, R. Zhang and T. Kuniya, The dynamics of an SVIR epidemiological model with infection age, *IMA J. Appl. Math.*, **81** (2016), 321–343.
- [38] J. Wang, J. Lang and F. Li, Constructing Lyapunov functionals for a delayed viral infection model with multitarget cells, nonlinear incidence rate, state-dependent removal rate, *J. Nonlinear Sci. Appl.*, **9** (2016), 524–536.
- [39] J. Wang, J. Lang and X. Zou, Analysis of an age structured HIV infection model with virus-to-cell infection and cell-to-cell transmission, *Nonlinear Anal. Real World Appl.*, **34** (2017), 75–96.
- [40] J. Wang, R. Zhang and T. Kuniya, Global dynamics for a class of age-infection HIV models with nonlinear infection rate, *J. Math. Anal. Appl.*, **432** (2015), 289–313.
- [41] J. Wang, R. Zhang and T. Kuniya, A note on dynamics of an age-of-infection cholera model, *Math. Biosci. Eng.*, **13** (2016), 227–247.
- [42] J. I. Weissberg, et al., Survival in chronic hepatitis B: An analysis of 379 patients, *Ann. Intern. Med.*, **101** (1984), 613–616.
- [43] R. Xu and Z. Ma, An HBV model with diffusion and time delay, *J. Theor. Biol.*, **257** (2009), 499–509.
- [44] R. Xu, Global stability of an HIV-1 infection model with saturation infection and intracellular delay, *J. Math. Anal. Appl.*, **375** (2011), 75–81.
- [45] Y. Yang, S. Ruan and D. Xiao, Global stability of an age-structured virus dynamics model with Beddington-Deangelis infection function, *Math. Biosci. Eng.*, **12** (2015), 859–877.
- [46] H. Zhu and X. Zou, Impact of delays in cell infection and virus production on HIV-1 dynamics, *Math. Med. Biol.*, **25** (2008), 99–112.

Received January 25, 2016; Accepted October 30, 2016.

E-mail address: wslheda@163.com

E-mail address: wujh@mathstat.yorku.ca

E-mail address: rong2@oakland.edu